Outcomes research in chronic viral hepatitis C: Effects of interferon therapy

Canadian Journal of Gastroenterology

Volumn 14, Issue SUPPL. B, 2000, Pages

  Bonkovsky, Herbert L ^a,b   Woolley, J Michael ^c  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b University of Massachusetts   (United States)

^c AMGEN INC   (United States)

Author keywords

Chronic hepatitis C; Cost effectiveness; Health related quality of life; Hepatitis; Interferon; Relapse; Treatment response; Virology

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

CLASSIFICATION; COST BENEFIT ANALYSIS; ECONOMICS; HEPATITIS C; HUMAN; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; QUESTIONNAIRES; RIBAVIRIN;

EID: 0034222231     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/127317     Document Type: Article

References (50)

1. Seeff LB. Natural history of hepatitis C. Hepatology 1997;26(Suppl):21S-8S.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26(Suppl):62S-5S.
3. Cella DF, Tulsky DS. Measuring quality of life today: methodological aspects. Oncology 1990;5:29-38.
4. Patrick DL, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press, 1993.
5. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. JAMA 1995;273:59-65.
6. Principles for the Review of Pharmacoeconomic Promotion (Draft). FDA Advertising and Promotion Manual, Appendix II. Rockville: United States Food and Drug Administration, 1995:A121-4.
7. Bergner M, Bobbit RA, Kressel S, Pollard WE, Gilson BS, Morris JR. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure. Int J Health Serv 1976;6:393-415.
8. Carter WB, Bobbit RA, Bergner M, Gilson BS. Validation of an interval scaling: the sickness impact profile. Health Serv Res 1976;11:516-28.
9. Pollard WE, Bobbit RA, Bergner M, Martin DP, Gilson BS. The sickness impact profile: reliability of a health status measure. Med Care 1976;14:146-55.
10. Bergner M, Bobbit RA, Pollard WE, Martin DP, Gilson BS. The sickness impact profile: validation of a health status measure. Med Care 1976;14:57-67.
11. Bergner M, Bobbit RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
12. Damiano AM. The Sickness Impact Profile. Massachusetts: Medical Outcomes Trust, 1995.
13. Abell TL, Cutts TF, Cooper T. Effect of cisapride therapy for severe dyspepsia on gastrointestinal symptoms and quality of life. Scand J Gastroenterol 1993;28(Suppl):60-4.
14. Riether AM, Smith SL, Lewison BJ, Cotsonis GA, Epstein CM. Quality of life changes and psychiatric and neurocognitive outcome after heart and liver transplantation. Transplantation 1992;54:444-50.
15. Tarter RE, Switala J, Arria A, Plail J, Thiel DV. Quality of life before and after orthotopic hepatic transplantation. Arch Intern Med 1991;151:1521-6.
16. Stewart AL, Ware JE, eds. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham: Duke University Press, 1992.
17. Brook RH, Ware JE Jr, Davies-Avery A, et al. Overview of adult health status measures fielded in RAND's health insurance study. Med Care 1979;17(7 Suppl):iii-x, 1-131.
18. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide. Boston: Nimrod Press, 1993.
19. Martin C, Marquis P, Bonfils S. A quality of life questionnaire adapted to duodenal ulcer therapeutic trials. Scand J Gastroenterol 1994;206(Suppl 29):40-3.
20. Adams PC, Ghent CN, Grant DR, Wall WJ. Employment after liver transplantation. Hepatology 1995;21:140-4.
21. Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE Jr. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998;7:39-55.
22. Davis GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther 1994;16:334-43.
23. Carithers RL, Sugano D, Bayliss M. Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci 1996;41(Suppl):75-80.
24. Hunt CM, Dominitz JA, Philips B, et al. Effect of interferon-α treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997;42:2482-6.
25. Foster GR, Boldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
26. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29:264-70.
27. Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Hepatology 1997;26:747-54.
28. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997;127:875-81.
29. Bennett WG, Pauker SG, Davis GL, Wong JB. Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C. Dig Dis Sci 1996;41:56S-62S.
30. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.
31. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74.
32. McHutchison JG, Woolley JM, Nyberg LM. Cost effectiveness of consensus interferon therapy for chronic HCV infection. Hepatology 1997;26:421A. (Abst)
33. Bennett WG, Inoue Y, Beck JR, Pauker SG, Davis GL. Justification of a single 6-month course of interferon (IFN) for histologically mild chronic hepatitis C. Hepatology 1995;22:290A. (Abst)
34. Kim WR, Poterucha JJ, Gross JB, Dickson ER, Evans RW. Cost-effectiveness of 12-months of interferon treatment for chronic hepatitis C. Hepatology 1996;26:A1233. (Abst)
35. Davis GL, Beck JR, Farrell G, Poynard T. Prolonged course versus 6-months of interferon alpha or no treatment in patients with histologically mild chronic hepatitis C: a decision analysis. Gastroenterology 1997;112:A1252. (Abst)
36. Kareemi M, Peltekian KM. Cost-effectiveness of interferon treatment for chronic hepatitis C. Hepatology 1996;26:597A. (Abst)
37. Heathcote J, Lee S, Pare P, Haider S, Beck B. Cost-effectiveness evaluation of a single course of interferon-alpha 2B in patients with histologically mild chronic hepatitis C: a Canadian analysis. Hepatology 1998;28:377A. (Abst)
38. Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interferon in the treatment of chronic hepatitis C. Med J Aust 1994;160:268-72.
39. Joliot E, Vanlemmens C, Kerleau M, et al. Analyse cout-efficacite du traitement de l'hepatite chronique C. Gastroenterol Clin Biol 1996:20:958-67.
40. Munari LM, Piciotto C. Recombinant interferon α2b therapy of chronic hepatitis C in Italy: an economic analysis. Forum Trends Exp Clin Med 1996;6:347-53.
41. Garcia de Ancos JL, Roberts JA, Dusheiko GM. An economic evaluation of the costs of interferon treatment of chronic active hepatitis due to hepatitis B or Cvirus. J Hepatol 1990;11:S11-8.
42. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alpha: an economic appraisal. Hepatology 1995;22:1863-82.
43. Younossi ZM, McHutchison JG. Interferon treatment of chronic HCV infection: an economic analysis of different strategies. Gastroenterology 1996;110:A47. (Abst)
44. Bennett WG, Wong JB, Koff RS, Ishida H, Beck JR, Pauker SG. What is the optimal pretreatment evaluation of chronic hepatitis C? Hepatology 1996;25:1029A. (Abst)
45. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C. JAMA 1998;280:2088-93.
46. McHutchison JG, Woolley JM, Nyberg LM. Cost effectiveness of retreatment with consensus interferon for chronic hepatitis C. Hepatology 1997;26:421A. (Abst)
47. Wong JB, Davis GL, Pauker SG. Cost-effectiveness of ribavirin/interferon alpha-2B after interferon relapse in chronic hepatitis C. Hepatology 1998;28:591A. (Abst)
48. Kim WR, Poterucha JJ, Dickson ER, Gross JB: Economic analysis of interferon/ribavirin treatment in patients with chronic hepatitis C who relapse following initial interferon therapy. Gastroenterology 1998;114:A1274. (Abst)
49. Kim WR, Poterucha JJ, Dickson ER, Gross JB. Cost-effectiveness of interferon/ribavirin treatment among nonresponders to initial interferon therapy for chronic hepatitis C. Hepatology 1998;28:231A. (Abst)
50. Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-43.